Ask Amy: First cancer hits, then heartbreak follows – The Providence Journal

Dear Amy,

Three years ago, I was diagnosed with bone cancer.

I went through 2 years of chemotherapy and six months of stem cell treatment.

I am now deemed to be cancer-free, and I feel great compared to how I felt in those three years.

During that time, I was with a woman (for eight years). We did everything together: Movies, dinners, road trips. Never had an argument. Never raised our voices at each other. My family and friends all loved her, as did I.

She treated me lovingly when I was sick, but of course when I was ill, I couldn't do the things we used to do. I hated that. My sex drive was gone. But I got better. I started feeling like my old self.

Then I was hit with a bombshell. She left me two months after I got well.

I was crushed. Heartbroken. I cried like a baby. I asked her why, and she said she felt like she was only existing. Not living.

But I was getting better!

I think that she met someone while I was ill, and she chose the other person. It hurts so deeply. My family, friends and her daughter were devastated.

She said, "We both need to move on with our lives," and I'm trying, but it's hard.

What do I do now? Besides go on with my life?

I'm working again, but it is tough by myself. I know I won't give up or give in, but this still hurts.

Do you have any words of wisdom for me?

Heartbroken in Dallas

Conventional wisdom might suggest that someone who hangs in there through the worst of things would then breathe a sigh of relief and commit to being there during recovery. But people leave. Your partner might have been exhausted by the caregiving she did during the worst of your illness.

I suspect that she might have wanted to leave just before, or maybe during your illness, but hung in there out of duty, guilt, loyalty, or compassion for you.

And what you must do now is go on with your life.

You are already doing this, in gradual steps that will become strides. Your recovery from this extremely painful breakup might parallel your recovery from cancer. Look at each day and celebrate your smaller victories. Write them down: A good day at work, a conversation with a friend, a creative project started or completed, an extra lap around the track, increased physical strength, another day of cancer-free living. You are demonstrating impressive resilience and strength. Recognizing that - deep down - will be an important building block for the new and improved you.

Dear Amy,

Every time my mom put dinner on the table I said, "Thank you," up until her death, and I am 56.

It is not just a family thing. When I prepare meals for friends, family, work colleagues or when we go out, it seems that saying thank you after a meal is the norm.

I now live with my fiance. His son just spent a month visiting us.

Every night I prepared and provided a healthy, home-cooked meal: Garden vegetables, shrimp, filet, pork, fish, different salads and grains.

Never once did I get a "thank you."

The last night, I even said, "I hope a different meal routine and food variety was a nice change." He actually said, "Nah, I always manage."

The lack of expression of gratitude infuriates me.

To be fair, most other aspects of the visit went well.

What are my best options to communicate this? It would be hard to cover up my resentment.

Gracious, Resentful Cook

Don't blame your fiance's son for not biting the hook during your attempt to fish for gratitude and a compliment. He sounds unsophisticated.

But there is another person at the table: his father. Your fiance should model kindness, respect and gratitude acknowledging your effort before eating and thanking you afterward and show his son that a grateful diner also clears the table and cleans up after a delicious meal.

Dear Amy,

I'm curious why the "Anxious Wife" whose husband didn't do enough housework neglected to state the working (outside the home) status of her and/or her husband.

Surely, if one of them is the major breadwinner, then the stay-at-home partner would be expected to perform more of the chores?

Need Clarification

"Anxious Wife" said she "needed help" with some tasks, and (regardless of their work status) I took her word for it.

Write to Ask Amy, P.O. Box 194, Freeville, NY 13068, or email askamy@amydickinson.com.

More:
Ask Amy: First cancer hits, then heartbreak follows - The Providence Journal

Ken Shamrock Credits Stem Cell Treatment For Being Able To Wrestle In Impact At 56 – 411mania.com

In an interview with TV Insider, Ken Shamrock spoke about how hes able to still wrestle in Impact Wrestling even at the age of 56, which he says is due to a stem cell treatment. Here are highlights:

On being in Impact Wrestling in 56: Its fun to see where I am now and look back to where I was a year or year-and-a-half ago. I basically have been out of wrestling and MMA. I took a year off. Then I had to see if I could still be in the ring. I went to Battle Championship Wrestling in Australia and did things I didnt think I could do. I did some BioXcellerator in Colombia. My body has responded well to that treatment. Being out of any competitive sport and coming back and feeling great, its almost like Ive been given the fountain of youth all over again. Ive been able to do things I actually havent done before. Now Im diving over the top rope and doing these showstoppers. To see my body respond after the layoff and the stem cell I got from BioXcelleratorit all came together, and I felt great. Thats where Im at today. People are watching me saying, How can he do that? Im fortunate the treatments have worked well for me. Im excited to be part of Impact with the Bound for Glory coming up and being inducted into the Hall of Fame. You couldnt ask for anything better.

On the Impact locker room: Since I came in, they were just starting to make those moves and bringing in different people. There were some people who had their past catch up with them. They were forced to get rid of some talent. You wonder if youre going downward because you lost some talent, but Impact to me has improved the roster by going out and finding all this talent out there to come in and fill those spots. Its exciting to see where it is right now. When I got there, its fun to watch how fast Impact was growing, how hard people are working. The dedication that is going on behind the scenes and in the ring. When youre part of a group where everyone wants to succeed, but you are not trying to step on each others toes and [instead] work together to get there, its a great environment. I was part of that at one time in WWF when they lost all this talent to WCW. They were having those wars and losing them. Then to see everyone bond together and do the job and work together with a common goal to put on the best performance There then was some big-time star power, but it took time to get there. You see guys like Bret Hart and Stone Cold Steve Austin become mega stars and The Rock and The Undertaker. There is a common goal to be successful at Impact but not try to push everybody down. Put on a great show with whoever youre working with and bring the best out of them.

On why he wanted The Rock to induct him: In life there are always people that are important pieces to your journey. They helped take you to where you needed to go and vice versa. The Rock had a career in college football with an opportunity to get to the pros from Miami. Then he chose to go into wrestling. I did my career in fighting and MMA and did well. Of course, I was going in a different direction. So I think we caught each other at a time where we were excited to find who we were and what we would become. When Vince [McMahon] put us together, it was like iron sharpening iron. I believe we really found out who we were in pro wrestling when we were able to work our programs together.

We had some great matches and were able to talk about things on the road and figure out what worked and didnt work. We were able to rise to where we are today off each other while working together. After his run, he went to the sky. I went in a different direction, but I had a similar success. Its awesome to look back on the journeys that you traveled, especially during times when you are recognized as being one of the greats and going into the Hall of Fame. You want to be able to include people who were so significant in that journey. The Rock was very significant in my journey. Thats why I reached out to him. There are several others that have also been important to the journey too. Its going to be fun to see how it all unfolds and the people involved that night. Im honored.

The rest is here:
Ken Shamrock Credits Stem Cell Treatment For Being Able To Wrestle In Impact At 56 - 411mania.com

Robust Growth Of The Animal Stem Cell Therapy Market Predicted Over The Forecast Period 2017 2025 – Aerospace Journal

Animal Stem Cell Therapy Market Insights 2018, is a professional and in-depth study on the current state of the global Animal Stem Cell Therapy industry with a focus on the Global market. The report provides key statistics on the market status of the Animal Stem Cell Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2018-2025 global Animal Stem Cell Therapy market covering all important parameters.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

The key points of the Animal Stem Cell Therapy Market report:

The report provides a basic overview of the Animal Stem Cell Therapy industry including its definition, applications and manufacturing technology.

The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2018-2025 market shares for each company.

Through the statistical analysis, the report depicts the global total market of Animal Stem Cell Therapy industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2018-2025 market development trends of Animal Stem Cell Therapy industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

The report makes some important proposals for a new project of Animal Stem Cell Therapy Industry before evaluating its feasibility.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For competitor segment, the report includes global key players of Animal Stem Cell Therapy are included:

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

Reasons to Purchase this Report:

* Estimates 2018-2025 Animal Stem Cell Therapy market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Originally posted here:
Robust Growth Of The Animal Stem Cell Therapy Market Predicted Over The Forecast Period 2017 2025 - Aerospace Journal

Stem Cell Therapy Market: Applications and Regional Insights During the Forecasted Period 2020-2030 – TechnoWeekly

Prophecy Market Insights has recently published the Stem Cell Therapy informational report which evaluates market size, growth rate, profit margin, raw material availability, impact strength, competition, technology, and environmental and legal factors.

The report covers all recent trends, opportunities, drivers, and restraints of the Stem Cell Therapy market coupled with their impact on demand over the forecast period. Additionally, the report provides a comprehensive view of the market by offering exhaustive value chain analysis. It provides in-depth information about value addition at each stage of the value chain.

Comprehensive information pertaining to fire alarm systems and its properties is provided in this section. This section also highlights the inclusions and exclusions, which help readers to understand the scope of the market report.

This segment includes factors that have emerged as key successful factors and strategies adopted by key market participants.

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3811

The Stem Cell Therapy market report provides a detailed analysis of market players according to its production footprint, market share, and growth rate. The report also covers SWOT analysis (strengths, weaknesses, opportunities, and threats) of the players. Besides, the Stem Cell Therapy market study depicts the recent launches, R&D projects, agreements, and business strategies of the market players including market segmentation and regional analysis of the market.

The Stem Cell Therapy market study covers both the top-down and bottom-up approaches that have been used to calculate and authenticate the market size and estimate the scenario of various sub-markets in the global market. The report estimation size of the market both in terms of volume (x units) and value (Mn/Bn USD).

Stem Cell Therapy Market by Top Manufacturers:

Scope of the Market Research Report:

The report takes into account the impact of the novel COVID-19 pandemic on the market and provides a clear assessment of the estimated market fluctuations throughout the forecast period.

Important Questions Answered in Stem Cell Therapy Market Report:

Segmentation Overview:

Global Stem Cell Therapy Market, By Treatment Type:

Global Stem Cell Therapy Market, By Cell Source:

Global Stem Cell Therapy Market, By Indication:

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/3811

Reasons to purchase the XYX market:

Provides recent collaborations, mergers, acquisitions, and partnerships along with regulatory framework across vast regions impacting the market trajectory

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Original post:
Stem Cell Therapy Market: Applications and Regional Insights During the Forecasted Period 2020-2030 - TechnoWeekly

Catalent to Produce BrainStorm’s NurOwn Cell Therapy for ALS – ALS News Today

Catalent Biologics has agreed to manufactureNurOwn, the cell-based therapy by BrainStorm Cell Therapeuticsbeing evaluated in a soon-to-conclude pivotal trial as a possible treatment of amyotrophic lateral sclerosis (ALS).

With this agreement, Catalent will produce NurOwn under current Good Manufacturing Practices standards set to ensure that batches of a medicine are produced with consistent high quality at its new 32,000-square-foot cell therapy manufacturing facility in Houston.

We are proud to have a partner in Catalent whose excellence in manufacturing quality therapies will support commercial supply of NurOwn, Chaim Lebovits, BrainStorms CEO, said in a press release.

With NurOwn, a patients mesenchymal stem cellsare collected from the bone marrow and treated in the lab to produce proteins called neurotrophic factors (NTFs), compounds that promote nervous tissue growth and survival. (Mesenchymal stem cells, orMSCs, are stem cells that can differentiate into a variety of other cell types.)

The modified cells called MSC-NTF cells are then injected into the patients spinal cord, where their NTFs are expected to promote the growth and survival of nerve cells, which are damaged over the course of ALS.

Using a patients own cells as a therapy minimizes the risk of an immune reaction, as might occur with cells from a donor.

The U.S. Food and Drug Administration has given NurOwn bothfast track and orphan drugdesignations to support and speed its development for ALS. The medicine also received orphan drug designation from the European Medicines Agency.

We know that ALS patients are in urgent need of a new treatment option. If NurOwn is successful in the current clinical trials, this agreement will be integral to ensuring rapid access for patients, Lebovits added.

NurOwn showed an ability to slow progression in people with fast-progressing disease in a Phase 2 trial (NCT02017912). This led Brainstorm to open a Phase 3 trial (NCT03280056)to confirm those findings in a larger group of ALS patients.

The trial, taking place at six sites in the U.S., enrolled 200 patients and randomly assigned them to either NurOwn or a placebo, given in three intrathecal (into the spinal cord) injections at two-month intervals.

Researchers are evaluating NurOwns effectiveness using therevised amyotrophic lateral sclerosis functional rating scale(ALSFRS-R), which assesses such daily life abilities as swallowing, speaking, dressing and washing oneself, climbing stairs, and turning over in bed.

Its primary goal is to determine whether NurOwn outperforms a placebo at reducing the rate of decline in ALSFRS-R scores over six months. A change of 1.25 points or more in ALSFRS-R scores each month, compared to scores recorded prior to treatment, defines a responder.

Other trial goals include safety, the number of patients whose disease has not progressed, total ALSFRS-R decline, and overall survival. Samples of blood and cerebrospinal fluid will also be collected to evaluate biomarkers, like neurotrophic factors and immune molecules, in response to the treatment.

BrainStorm expects to deliver top-line results this year; the study is set to fully conclude in December.

Should results be positive and NurOwn be approved for clinical use, BrainStorm and Catalent will consider extending their partnership to allow for commercial manufacturing of NurOwn at the Houston facility.

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

Total Posts: 45

Ins holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Cincias e Tecnologias and Instituto Gulbenkian de Cincia. Ins currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Go here to see the original:
Catalent to Produce BrainStorm's NurOwn Cell Therapy for ALS - ALS News Today

NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia – BioSpace

GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Neximmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has signed a research initiative related to its AIM nanoparticle technology with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.

City of Hope is a participating clinical site in the ongoing Phase 1/2 study of NEXI-001. The cancer center will leverage both patient samples from the ongoing NexImmune Phase 1/2 clinical study of NEXI-001 in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic stem cell transplantation and the centers tumor repository bank of primary leukemia samples, one of the largest collections in the world, to drive the research.

NEXI-001 is a cellular product candidate that contains populations of naturally occurring CD8+ T cells directed against multiple antigen targets for AML, and it is the first clinical product generated by the Companys AIM nanoparticle technology.

NexImmune has developed a unique and versatile technology platform that lends itself very effectively to important areas of ongoing research in the field of AML, said Guido Marcucci, M.D., Chair and Professor with City of Hopes Department of Hematologic Malignancies Translational Science. Our collective goal is to translate future research findings into new, more effective T cell immunotherapies to the benefit of these very difficult to treat patients.

A key objective of the research will focus on the identification of new antigen targets that are expressed on both leukemic blasts as well as leukemic stem cells, and those which represent survival proteins to both. Once identified, these antigen targets will be loaded on NexImmune AIM-nanoparticles to expand antigen-specific CD8+ T cells, and evaluated in pre-clinical models for anti-tumor potency, tumor-specific killing, and response durability.

In addition, the research initiative will aim to further understand different mechanisms of tumor escape, such as tumor antigen and human leukocyte antigen (HLA) downregulation due to immune pressure.

Research between NexImmune and City of Hope will inform a scientific understanding of how the immune system can address certain tumor escape mechanisms to more effectively fight aggressive cancers like AML, and how this might be accomplished with NexImmunes AIM technology and T cell products, said Monzr Al Malki, M.D., Director of City of Hopes Unrelated Donor BMT Program and Haploidentical Transplant Program and an Associate Clinical Professor with Department of Hematology and Hematopoietic Cell Transplantation. Based on our current clinical experience with this technology, were excited to learn what more this research will tell us.

City of Hope is a world-class clinical research institution that has built one of the largest banks of leukemia samples in the world, said Han Myint, M.D., NexImmune Chief Medical Officer. The depth of expertise that Drs. Marcucci, Al Malki and their team bring to this research initiative will help NexImmune continue to develop innovative products that can help patients with AML and other hard-to-treat cancers.

City of Hope is a leader inbone marrow transplantation. More than 16,000 stem cell and bone marrow transplants have been performed at City of Hope, and more than 700 are performed annually. City of Hopes BMT program is the only one in the nation that has had one-year survival above the expected rate for 15 consecutive years, based on analysis by the Center for International Blood and Marrow Transplant Research.

About NexImmune NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The AIM technology is designed to generate a targeted T cell-mediated immune response and is initially being developed as a cell therapy for the treatment of hematologic cancers. AIM nanoparticles (AIM-np) act as synthetic dendritic cells to deliver immune-specific signals to targeted T cells and can direct the activation or suppression of cell-mediated immunity. In cancer, AIM-expanded T cells have demonstrated best-in-class anti-tumor properties as characterized by in vitro analysis, including a unique combination of anti-tumor potency, antigen target-specific killing, and long-term T cell persistence. The modular design of the AIM platform enables rapid expansion across multiple therapeutic areas, with both cell therapy and injectable products.

NexImmunes two lead T cell therapy programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy, respectively. The Companys pipeline also has additional preclinical programs, including cell therapy and injectable product candidates, for the treatment of oncology, autoimmune disorders, and infectious diseases.

For more information, visit http://www.neximmune.com.

Media Contact: Mike Beyer Sam Brown Inc. Healthcare Communications 312-961-2502 mikebeyer@sambrown.com

Investor Contact: Chad Rubin Solebury Trout +1-646-378-2947 crubin@soleburytrout.com

Read the rest here:
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia - BioSpace

Stem Cell Therapy Market Highest Growth by 2025 with Leading Players – The Think Curiouser

The global Stem Cell Therapy Market includes a thorough assessment of the industrys entire ecosystem, including regional and country-specific details of manufacturing activities, technological innovations, new investments, and milestones for market expansion. The report provides an exclusive overview of the competitive spectrum to identify major giants and ambitious players seeking to easily drive market penetration in the global Stem Cell Therapy Market ecosystem. The details of the COVID-19 impact and possible damage recovery plan have been discussed at length to guide important business decisions. The report is ready to reference documents that share important details of the market from a historical point of view, allowing readers to measure concurrent developments to make accurate growth guesses and make predictive assessments.

Download Sample PDF Brochure with Covid-19 Updates @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

In addition to adding new Stem Cell Therapy Market reports to the league, the extensively researched and prepared repository is constantly updated to ensure real-time status. Our in-house research experts continue to adhere to internationally recognized research practices to stay ahead of the competition. Our well-updated online research archives stand out across the globe and in regional areas and boast a constantly growing clientele with a dedicated presence in specific countries. As a highly preferred research and consulting service provider, we strive to address multiple industries with in-depth insights that favor error-free deductions and forward-looking insights that support future business decisions.

The main purpose of this detailed business intelligence report is to closely follow development patterns, highlight the dominant popular trends, and identify new trend analysis and new opportunities influencing value and volume-based revenue in the global Stem Cell Therapy Market. Research findings show that new and existing players across market platforms are keen to reach logical and relevant business considerations where they can leverage solid leads in addition to effectively brainstorming profitable business decisions to secure stable leads. And has been meticulously presented based on secondary research practices. Long-term revenue generation despite major dynamics changes and catastrophic changes that have a profound impact on the overall growth trajectory of the global Stem Cell Therapy Market.

Get discount on purchase at: https://www.adroitmarketresearch.com/researchreport/purchase/691?utm_source=re

Research findings show that new and existing players across market platforms are keen to reach logical and relevant business considerations where they can leverage solid leads in addition to effectively brainstorming profitable business decisions to secure stable leads. And has been meticulously presented based on secondary research practices. Long-term revenue generation despite major dynamics changes and catastrophic changes that have a profound impact on the overall growth trajectory of the global Stem Cell Therapy Market.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

Primary Focus of the Stem Cell Therapy Market Report, Enlisted

1. Readers are presented with market insider report commencing with the overview section 2. Later in the report, details on manufacturer information, leading market participants as well as other key players have also been included. 3. Relevant details on market production, capacity, revenue generation in terms of value and volume based metrices have also been encapsulated in the report. 4. Above mentioned details have been systematically presented based on region as well as country-specific developments, with details about export and import activities. 5. Details pertaining to market segmentation have also been included in the Stem Cell Therapy Market report which are classified into type and application. Additional details on technological applications and milestones have also been included in the report. 6. Readers can also spot other vital details inclusive of industrial chain, downstream and upstream developments besides including details in other stakeholders such as traders, distributors as well as downstream buyers.

Browse full research report @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

Chapter1. Executive Summary Chapter2. Research Methodology Chapter3. Market Outlook Chapter4. Global Stem Cell Therapy Market Overview, By Type Chapter5. Global Stem Cell Therapy Market Overview, By Application Chapter6. Global Stem Cell Therapy Market Overview, By Region Chapter7. Company Profiles

View post:
Stem Cell Therapy Market Highest Growth by 2025 with Leading Players - The Think Curiouser

Bayer to pay $2B upfront for AskBio to drive gene therapy expansion – FierceBiotech

Bayer has struck a deal to acquire Asklepios BioPharmaceutical for $2 billion upfront. The deal, which features an additional $2 billion in milestones, will give Bayer control of an adeno-associated virus (AAV) gene therapy platform and a pipeline led by clinical-phase treatments for Parkinsons, Pompe disease and congestive heart failure.

Asklepios, known as AskBio, is a veteran of the gene therapy space. Jude Samulski, a pioneer of AAV vectors, founded the company in 2001. Since then, AskBio has built out an AAV platform and an associated high-yield cell line, and it's worked with Columbus Venture Partners to establish gene therapy manufacturing capacitya scarce, valuable resource in the booming industry. The manufacturing site is run by Viralgen, the CDMO AskBio set up with Columbus.

AskBio, which provided the self-complementary DNA technology used in Novartis approved gene therapy Zolgensma, has used its capabilities to develop an internal pipeline of neuromuscular, central nervous system, cardiovascular and metabolic gene therapies.

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

Germanys Bayer has valued the assets at $2 billion upfront, plus the same again in success-based milestones. Three-quarters of the success-based milestones are tied to events scheduled to happen in the next five years.

Bayer sees potential to use AskBios platform to tackle relatively large, polygenetic indications. The company also foresees opportunities to use the CDMO business as the foundation for partnerships involving AAV therapies.

Once the deal closes, likely in the fourth quarter, Bayer will allow AskBio to operate autonomously as part of a new cell and gene therapy unit in a bid to preserve its entrepreneurial culture. The cell and gene therapy unit will bundle Bayer's activities in this area moving forward in order to establish an innovation ecosystem for the participating partners, the German company said.

Bayer has begun to build out that ecosystem in recent years. Last year, Bayer paid $240 million upfront to acquire the almost 60% of BlueRock Therapeutics that it didnt already own, giving it access to an induced pluripotent stem cell (iPSC) platform and associated pipeline. Shortly before that, Bayer invested $215 million in Century Therapeutics, another iPSC startup.

The series of deals has given Bayer full or partial stakes in a clutch of cell and gene therapy programs, plus infrastructure to develop and manufacture the assets. Other companies have embarked on similar strategies, notably in the gene therapy space, leading to a series of deals that have given companies including Biogen, Novartis and Roche control of therapeutic assets and infrastructure.

View original post here:
Bayer to pay $2B upfront for AskBio to drive gene therapy expansion - FierceBiotech

Stem Cell Therapy Market to Witness Growth Acceleration During 2020-2025 – Aerospace Journal

The latest Stem Cell Therapy market research added by Market Study Report, LLC, delivers a concise outline regarding the potential factors likely to drive the revenue growth of this industry. The report delivers valuable insights on market revenue, SWOT Analysis, market share, profit estimation and regional landscape of this business vertical. Moreover, the report focuses on significant growth factors and obstacles accepted by market leaders in the Stem Cell Therapy market.

The Stem Cell Therapy market report offers a comprehensive analysis of this industry vertical, emphasizing on the key growth stimulants, opportunities, and constraints projected to shape the market dynamics over the forecast period.

Request a sample Report of Stem Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2422751?utm_source=aerospace-journal.com&utm_medium=AG

As per industry experts, the market is anticipated to grow significantly, registering a CAGR of XX% over the analysis period of 2020-2025.

Instabilities in the supply & demand channels due to the stringent lockdown measures imposed to address the COVID-19 pandemic has left numerous companies in disarray. Speaking of the ambiguity of revenues in the near term, businesses are expected to face hindrance even once the economy recovers from the pandemic.

Additionally, the report offers a holistic assessment of various industry segments to infer the revenue projections for the market over the study duration.

Key inclusions of the Stem Cell Therapy market report:

Ask for Discount on Stem Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2422751?utm_source=aerospace-journal.com&utm_medium=AG

Comprehensive assessment of all opportunities and risks in the Stem Cell Therapy market.

Stem Cell Therapy Market segments covered in the report:

Product spectrum:

Applications spectrum:

Regional analysis: North America, Europe, Asia-Pacific, South America, Middle East and Africa

Competitive landscape:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-stem-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Some of the Major Highlights of TOC covers:

Executive Summary

Manufacturing Cost Structure Analysis

Development and Manufacturing Plants Analysis of Stem Cell Therapy

Key Figures of Major Manufacturers

Related Reports:

1. Global Natural Killer Cell Therapy Market 2020 by Company, Regions, Type and Application, Forecast to 2025 This report includes the assessment of Natural Killer Cell Therapy market size for value and volume. Both top-down and bottom-up approaches have been used to estimate and validate the Natural Killer Cell Therapy market, to estimate the size of various other dependent submarkets in the overall market. Read More: https://www.marketstudyreport.com/reports/global-natural-killer-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

2. Global Allergen Blocker Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Allergen Blocker Market report characterize imperative Portion and contenders of the market regarding market estimate, volume, esteem. This report likewise covers every one of the locales and nations of the world, which demonstrates a territorial improvement status, it additionally incorporates Business Profile, Introduction, Revenue and so on. Read More: https://www.marketstudyreport.com/reports/global-allergen-blocker-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Read More Reports On: https://www.marketwatch.com/press-release/Unified-Network-Management-Market-Size-Technological-Advancement-and-Growth-Analysis-with-Forecast-to-2025-2020-10-26

Contact Us: Corporate Sales, Market Study Report LLC Phone: 1-302-273-0910 Toll Free: 1-866-764-2150 Email: [emailprotected]

Read more:
Stem Cell Therapy Market to Witness Growth Acceleration During 2020-2025 - Aerospace Journal

Animal Stem Cell Therapy Market Analysis 2019 Growth by Top Companies and Trends by Types, Treatment, Diagnosis and Application Forecast Analysis to…

Global Animal Stem Cell Therapy Market research report presents a comprehensive overview of market size, share, evolution, trends, and forecast, and growth opportunities of Animal Stem Cell Therapy market by product type, application, key manufacturers and key regions and countries. This report offers comprehensive analysis on global Animal Stem Cell Therapy market along with, market trends, drivers, and restraints of the Animal Stem Cell Therapy market. In-depth study of market size with data Tables, Bar & Pie Charts, and Graphs & Statistics which helps easy to understand detailed breakdown of market.

Note: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2638488&source=atm

Segment by Type, the Animal Stem Cell Therapy market is segmented into Dogs Horses Others

Segment by Application, the Animal Stem Cell Therapy market is segmented into Veterinary Hospitals Research Organizations

Regional and Country-level Analysis The Animal Stem Cell Therapy market is analysed and market size information is provided by regions (countries). The key regions covered in the Animal Stem Cell Therapy market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc. The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026. Competitive Landscape and Animal Stem Cell Therapy Market Share Analysis Animal Stem Cell Therapy market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Animal Stem Cell Therapy business, the date to enter into the Animal Stem Cell Therapy market, Animal Stem Cell Therapy product introduction, recent developments, etc. The major vendors covered: Medivet Biologics LLC VETSTEM BIOPHARMA J-ARM U.S. Stem Cell, Inc VetCell Therapeutics Celavet Inc. Magellan Stem Cells Kintaro Cells Power Animal Stem Care Animal Cell Therapies Cell Therapy Sciences Animacel

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2638488&source=atm

This detailed report on Animal Stem Cell Therapy market largely focuses on prominent facets such as product portfolio, payment channels, service offerings, applications, in addition to technological sophistication. The report lends versatile cues on market size and growth traits, besides also offering an in-depth section on opportunity mapping as well as barrier analysis, thus encouraging report readers to incur growth in global Animal Stem Cell Therapy market.

This comprehensive research- documentary on global Animal Stem Cell Therapy market is a holistic perspective of market developments, factors, dynamics, trends and challenges that decide growth trajectory of global Animal Stem Cell Therapy market.

Apart from highlighting these vital realms, the report also includes critical understanding on notable developments and growth estimation across regions at a global context in this report on Animal Stem Cell Therapy market.

These leading players are analyzed at length, complete with their product portfolio and company profiles to decipher crucial market findings. Additionally, the competitive landscape of the Animal Stem Cell Therapy market is also evaluated at length in the report, to identify and analyze leading service providers.

Geographically, the detailed analysis of consumption, revenue, Animal Stem Cell Therapy market share and growth rate, historic and forecast (2015-2026) of the following regions are covered-

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

All the notable Animal Stem Cell Therapy market specific dimensions are studied and analyzed at length in the report to arrive at conclusive insights. Further, a dedicated section on regional overview of the Animal Stem Cell Therapy market is also included in the report to identify lucrative growth hubs.

This Animal Stem Cell Therapy market also harps on competition intensity, thoroughly identifying and evaluating leading players in the Animal Stem Cell Therapy market and their growth stimulators. Besides these aforementioned factors and attributes of the Animal Stem Cell Therapy market, this report specifically decodes notable findings and concludes on innumerable factors and growth stimulating decisions that make this Animal Stem Cell Therapy market a highly profitable.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2638488&licType=S&source=atm

A thorough take on essential elements such as drivers, threats, challenges, opportunities are thoroughly assessed and analyzed to arrive at logical conclusions. As the report proceeds further, Even further in the report emphasis has been lent on current, historical, as well as future growth tendencies to make accurate growth estimations based on market size, value, volume, demand and supply trends as well as growth rate.

Other vital factors related to the Animal Stem Cell Therapy market such as scope, growth potential, profitability, and structural break-down have been innately roped in this Animal Stem Cell Therapy report to accelerate market growth. This research compilation on Animal Stem Cell Therapy market is a meticulous compilation of in-depth primary and secondary research. The report also lists ample understanding on various analytical practices such as SWOT and PESTEL analysis to guide optimum profits in Animal Stem Cell Therapy market. The report is a conscious attempt to unearth market specific developments to ignite growth specific market discretion.

For More Information Kindly Contact:

marketresearchhub

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Read the original post:
Animal Stem Cell Therapy Market Analysis 2019 Growth by Top Companies and Trends by Types, Treatment, Diagnosis and Application Forecast Analysis to...